IASO206 · In Vivo BCMA CAR-T — Multiple Myeloma CDP

Development Strategy

The program advances through four sequential stages, with conditional/accelerated approval sought on the >=4L pivotal package before or in parallel with the 1-3L confirmatory study. A direct head-to-head comparison with ex vivo CAR-T is not considered necessary.

1. BCMA Target & Product

Target rationale

B-cell maturation antigen (BCMA, TNFRSF17 / CD269) is one of the most clinically validated targets in multiple myeloma. It is mainly expressed on mature B cells, plasma cells and malignant plasma cells, and is largely absent from hematopoietic stem cells and most normal tissues. Compared with CD38 (also on erythrocytes, platelets and immune-cell subsets) and SLAMF7 (also on NK and some T cells), BCMA provides a more selective plasma-cell lineage target. Soluble BCMA (sBCMA), generated by gamma-secretase cleavage, can reflect tumor burden and may interfere with BCMA-targeted therapies through competitive binding.

Four BCMA-targeted modalities

• ADC — Belantamab mafodotin is the benchmark; re-established in combination regimens, but ocular/corneal toxicity and monitoring remain key limitations.
• Bispecific / T-cell engagers — Teclistamab, elranatamab and linvoseltamab recruit endogenous T cells; off-the-shelf with no leukapheresis, but repeated dosing, infection risk, hypogammaglobulinemia and IVIG burden differentiate them from one-time therapy.
• Ex vivo (autologous) CAR-T — Ide-cel, cilta-cel, Eque-cel and zevor-cel deliver deep responses, but require leukapheresis, individualized manufacturing, vein-to-vein time, lymphodepletion, limited center capacity and high cost.
• In vivo CAR-T — Generates CAR-T cells directly inside the patient via a systemic gene-transfer vector (targeted lentiviral vector or LNP), eliminating leukapheresis, ex vivo culture and individualized manufacturing, and potentially avoiding lymphodepletion. IASO206 belongs to this emerging class; early proof-of-concept comes from ESO-T01 and KLN-1010.

IASO206 features (condensed)

• Vector design — optimized self-inactivating lentiviral vector carrying a BCMA CAR transgene, designed for selective in vivo transduction of circulating T cells.
• CAR structure — BCMA-binding domain, hinge/transmembrane region, 4-1BB costimulatory domain and CD3zeta signaling domain, aiming for memory-like CAR-T cells with durable activity.
• Simplified administration — single IV without leukapheresis, ex vivo manufacturing or lymphodepletion (central differentiation versus autologous CAR-T).
• Lower treatment burden — avoiding lymphodepletion may reduce cytopenia, infection risk, hospitalization and IVIG burden.
• Scalable manufacturing — batch-produced viral-vector manufacturing may support broader access, lower cost and better commercial scalability than individualized cell manufacturing.

Competitive comparison

Late-line efficacy benchmarks across approved BCMA bispecifics and CAR-T products (source figures, with conditioning/route context):

Eque-cel (FUMANBA-1: ORR ~96%, CR/sCR ~74%) and cilta-cel (CARTITUDE — strongest ex vivo benchmark) anchor the deep-response bar; IASO206 should compete not on early ORR alone but on a full evidence chain of in vivo generation, persistence, MRD depth, durability, outpatient feasibility, lower infection/IVIG burden, scalability and long-term gene-therapy safety.

2. Business Value

Epidemiology

Multiple myeloma is the second most common hematologic malignancy, characterized by clonal plasma-cell expansion and end-organ damage (hypercalcemia, renal insufficiency, anemia, bone disease). Incidence rises strongly with age, and burden is expected to grow with population aging in both China and the United States.

• United States — approximately 35,000+ new MM cases annually, with a large prevalent population due to improved survival.
• China — approximately 30,000-35,000 new cases annually; lower age-standardized incidence but a large population base, with patients more often presenting at later stage with renal impairment.

Quantified unmet need

• Outcomes deteriorate with each additional line of therapy; late-line conventional regimens have limited ORR, short PFS and poor OS.
• Triple-class exposed/refractory patients have particularly poor outcomes and limited durable options.
• Ex vivo CAR-T provides deep responses but is constrained by leukapheresis, manufacturing time, center capacity, lymphodepletion, cost and manufacturing failure.
• Continuous T-cell-engaging antibodies are accessible but impose long-term dosing, infection monitoring, hypogammaglobulinemia, IVIG use and cumulative healthcare burden.

Eligible-patient funnel

Market share (at maturity) & value

Pricing should reflect the value of a one-time CAR-T-like therapy while acknowledging lower manufacturing complexity than autologous CAR-T — in the US, below ex vivo CAR-T but above annualized bispecific therapy if durability is proven; in China, lower pricing and reimbursement strategy will be central to uptake. A successful 1-3L randomized Phase III program would materially expand the peak-sales opportunity.

3. Clinical Trial Plan

Recommended sequence: (1) complete China FIH/Ib dose escalation and expansion; (2) fold the US, EU and other regions into one global program; (3) run the >=4L RRMM global single-arm pivotal study; (4) seek conditional/accelerated approval on that evidence; (5) directly run the 1-3L randomized Phase III confirmatory study versus regional SOC.

FIH / Ib (Phase Ia/Ib)

• Design — open-label dose escalation and expansion (3+3 or Bayesian).
• Population — RRMM, initially late-line; BCMA-targeted therapy-naive may be prioritized for mechanism demonstration.
• Objectives/endpoints — safety, DLTs, CRS/ICANS, in vivo CAR-T generation, vector biodistribution, viral shedding, RCL/RCR, insertion-site analysis; CAR transgene copies, CAR+ T-cell proportion, cytokines, ORR, CR/sCR, MRD negativity, DOR, PFS; define RP2D.

>=4L global single-arm pivotal

• Design — global, multicenter, open-label single-arm pivotal study covering US, EU and other major markets, with IRC assessment and central MRD testing.
• Population — >=4L RRMM in two prespecified cohorts: prior BCMA-targeted therapy and BCMA-targeted therapy-naive.
• Endpoints — primary ORR and/or CR/sCR with MRD negativity; key secondary: sustained MRD negativity, DOR, PFS, OS, safety, CRS/ICANS, infections, IVIG use, hospitalization, PROs, treatment-free interval.
• Sample size — approximately 120-180 patients overall, with cohort-specific assumptions and thresholds; final size depends on regulatory feedback and expected ORR/CR/MRD/DOR.
• Regulatory intent — support conditional/accelerated approval, then bridge to full approval.

1-3L randomized Phase III confirmatory

• Design — randomized, open-label, controlled Phase III; 1:1 randomization (no randomized Phase II validation step).
• Population — 1-3L RRMM; lenalidomide-refractory and BCMA-naive preferred.
• Comparator — IASO206 single IV at RP2D versus investigator-selected regional SOC (e.g. DPd, PVd, DVd, DKd/Kd, Isa-Pd); no ex vivo CAR-T comparator required.
• Endpoints — co-primary: MRD negativity + PFS; key secondary: CR/sCR, sustained MRD negativity, DOR, OS, safety, infection/IVIG burden, hospitalization, PROs, health economics. Stratify by prior lines, CD38 exposure/refractoriness, cytogenetic risk, ISS/R-ISS, renal function, region.
• Sample size — approximately 300-500 patients, 1:1, subject to MRD effect size, PFS hazard ratio, required events and regulatory alignment.

Phase IV / post-marketing

• Long-term follow-up for at least 15 years per gene-therapy expectations.
• Real-world effectiveness, safety, hospitalization, IVIG use, infection management and resource utilization.
• Expansion into earlier lines, high-risk populations, smoldering myeloma or combinations only after the core evidence package is mature; support conversion of conditional/accelerated approval to full approval.

4. Regulatory Considerations

IASO206 is both a cell-therapy-like immunotherapy and an in vivo gene-transfer product, so early engagement is essential. The first wave of questions covers classification, nonclinical package, vector targeting, RCL/RCR testing, insertion-site monitoring, viral shedding, reproductive risk, starting dose, DLT window, outpatient administration, CRS/ICANS management and long-term follow-up.

• FDA — position the >=4L global single-arm pivotal study as the first registration pathway via accelerated approval; align on single-arm acceptability, the two BCMA-exposure cohorts, MRD methodology, DOR/PFS maturity, the 1-3L confirmatory design, and LTFU obligations for an integrating vector.
• EMA — Scientific Advice on whether the >=4L study can support Conditional Marketing Authorization (CMA); GMO/environmental risk assessment, PIP timing, indirect contextualization versus ex vivo CAR-T/bispecifics, and acceptability of regional SOC control arms in the 1-3L study.
• NMPA — China FIH safety, dose selection, bridging to global data, MRD-testing consistency, role versus approved China BCMA CAR-T, and feasibility of conditional approval on global pivotal data plus China-specific evidence.
• PMDA — early engagement on Japan participation, bridging needs, LTFU, and Sakigake or conditional early approval if substantial benefit is shown.

5. Strategy & Governance

Milestones (key dates)

Go/No-Go criteria (four dimensions)

Differentiated evidence package

The program should prospectively capture in vivo CAR-T generation and persistence, MRD negativity and sustained MRD negativity (at 6 and 12 months), PFS, DOR, ORR/CR/sCR, reduced burden from no lymphodepletion, grade >=3 infections and IVIG use, outpatient feasibility, and long-term monitoring for insertional mutagenesis and RCL/RCR. IASO206 should be positioned as complementary to, not cannibalistic of, Eque-cel — the mature ex vivo BCMA CAR-T asset in China — expanding access through a scalable, no-leukapheresis, no-lymphodepletion approach, with shared KOL networks, treatment-center education, MRD/safety infrastructure and BCMA sequencing strategies.